I think you are mixing up something here:
“The ab/tau biomarkers pertain to anyone with AD, so an accelerated approval will not care about subgroups. This makes an AA route the more attractive commercial option, in my opinion;”
It similar to saying everyone with AD have AD, so no subgroup analysis is needed.
You are missing here that not every trial patient will respond to A2-73 in way that changes the abeta/tau ratio biomarker value to indicate assumed improvement and thus reasonable likely to reflect a clinical benefit.
Maybe only a small proportion of patients exhibit a positive change in abeta/tau, for example only those that have APOE3 alleles plus this and that characteristic. Those would then be selection biomarkers in a Precision Medicine trial ensuring a homogeneous cohort of presumed responders only.
Market Data 
Markets 
AI
